Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | J591 |
| Synonyms | |
| Therapy Description |
J591 is a monoclonal antibody that specifically targets the extracellular domain of the prostate-specific membrane antigen (PSMA), which may result in antitumor activity (PMID: 15837970, PMID: 32600929). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| J591 | huJ591 | PSMA Antibody 23 | J591 is a monoclonal antibody that specifically targets the extracellular domain of the prostate-specific membrane antigen (PSMA), which may result in antitumor activity (PMID: 15837970, PMID: 32600929). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02552394 | Phase I | J591 | J591 in Patients With Advanced Prostate Cancer and Unfavorable Circulating Tumor Cell Counts | Completed | USA | 0 |